论著

局部晚期乳腺癌患者腋窝淋巴结转移范围的影响因素分析

展开
  • 1. 上海交通大学医学院附属国际和平妇幼保健院乳腺科,上海 200030
    2. 上海交通大学医学院附属瑞金医院超声科,上海 200025

收稿日期: 2018-10-10

  网络出版日期: 2019-04-25

基金资助

国际和平妇幼保健院院级课题(GFY 5502);国际和平妇幼保健院优秀青年医师培育计划(GFY 9307)

Influencing factors of axillary lymph node metastasis in patients with locally advanced breast cancer

Expand
  • 1. Department of Breast, International Peace Maternity & Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
    2. Department of Ultrasound, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2018-10-10

  Online published: 2019-04-25

摘要

目的:研究局部晚期乳腺癌患者腋窝淋巴结转移程度的影响因素。方法:回顾性收集我院2008年4月到2018年4月腋窝淋巴结转移≥4枚的233例乳腺癌患者的临床病理资料,比较腋窝淋巴转移N2组(141例)和N3组(92例)患者间的年龄、分子分型[Luminal A分子分型、人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性,三阴性]、肿瘤大小、组织学分级、雌激素、孕激素受体表达、HER-2表达及Ki-67表达的差异。结果:N2组患者中肿瘤大小为T1、T2、T3、T4的百分比分别为46.1%、49.6%、2.8%、1.4%;N3患者中肿瘤大小为T1、T2、T3、T4的百分比分别为27.2%、58.7%、13.0%、1.1%,与N2组比较,N3组患者的肿瘤直径更大(P=0.002)。而N2组与N3组患者在年龄、分子分型、组织学分级及雌激素受体、孕激素受体、HER-2、Ki-67表达方面差异均无统计学意义(P>0.05)。结论:局部晚期乳腺癌淋巴结转移范围与肿瘤大小(T分期)显著相关,而与乳腺癌患者的年龄、分子分型、组织学分级及雌激素受体、孕激素受体、HER-2、Ki-67表达无关。

本文引用格式

王志威, 张晓晓, 王杰, 魏敏, 邵玉国, 籍敏, 杨莉, 何奇 . 局部晚期乳腺癌患者腋窝淋巴结转移范围的影响因素分析[J]. 诊断学理论与实践, 2019 , 18(2) : 189 -192 . DOI: 10.16150/j.1671-2870.2019.02.013

Abstract

Objective: To investigate the influencing factors of axillary lymph node metastasis in patients with locally advanced breast cancer. Methods: The clinical pathological data of 233 locally advanced breast cancer patients with at least 4 axillary lymph nodes metastasis from April, 2008 to April, 2018 in our hospital were collected retrospectively. The age, molecular type (luminal A/luminal B, HER-2 positive/negative, triple negative), tumor diameter, histological grade and the expression of ER/PR, HER-2, Ki-67 were compared between patients with N2 and N3 axillary lymph node metastasis. Results: Of the 233 locally advanced breast cancer patients, 141 patients were in Group N2 while 92 patients were in Group N3. The proportions of T1, T2, T3 and T4 in N2 group were 46.1%, 49.6%, 2.8% and 1.4%, respectively, whereas that in N3 group were 27.2%, 58.7%, 13.0% and 1.1%, respectively. The diameter of tumor was larger in N3 group than in N2 group(P=0.002). There was no statistical difference between Group N2 and N3 in terms of age, molecular type, histological grade, ER/PR expression, HER-2 expression and Ki-67 expression (P>0.05). Conclusions: In locally advanced breast cancer, the number of axillary lymph nodes metastasis is correlated significantly with the diameter of tumor (T stage). while no correlations with age, molecular type, histological grade, ER/PR expression, HER-2 expression and Ki-67 expression are found.

参考文献

[1] 谢文秀, 杨俊兰, 焦顺昌, 等. 乳腺癌分子分型与腋窝淋巴结转移相关性分析[J]. 解放军医学院学报, 2011, 32(7):708-711.
[2] van Calster B, Vanden Bempt I, Drijkoningen M, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive[J]. Breast Cancer Res Treat. 2009 Jan; 113(1):181-187.
[3] 庞琼, 南昊成, 马婕群, 等. 不同分子亚型乳腺浸润性导管癌的临床特征与预后分析[J]. 临床肿瘤学杂志, 2015, 21(2):132-136.
[4] 赵永富, 姚永庭. 青年女性乳腺癌分子分型及其与临床病理特征的关系[J]. 中国妇幼健康研究, 2015, 26(6):1185-1188.
[5] 王盛, 李娜. 乳腺浸润性导管癌最新分子分型及其临床病理特征分析[J]. 中国社区医师, 2015, 29(8):110-112.
[6] 曹静, 吕志排, 雷冬梅, 等. 乳腺癌的分子分型与临床病理特征及预后的关系[J]. 诊断学理论与实践, 2013, 12(4):466-469.
[7] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志, 2017, 27(9):695-759.
[8] Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J]. J Clin Oncol, 2013, 31(2):203-209.
[9] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9):2206-2223.
[10] 张绪良, 黄绪群. 分子分型在乳腺癌辅助治疗选择中的临床研究[J]. 现代肿瘤医学, 2015, 23(19):2747-2750.
[11] Inic Z, Zegarac M, Inic M, et al. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information[J]. Clin Med Insights Oncol, 2014, 8:107-111.
[12] 王芳, 郝春芳, 贾勇圣, 等.205 例初治转移性乳腺癌的临床病理特点和生存分析[J]. 中国肿瘤临床, 2014, 52(17):1103-1107.
[13] 沈镇宙, 邵志敏. 乳腺肿瘤学[M]. 上海科学技术出版社, 2005.
[14] Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma[J]. World J Surg, 2001, 25(6):767-772.
[15] 周淑玲, 杨文涛. 三阴性乳腺癌的临床病理特征及分子研究进展[J]. 中国癌症杂志, 2013, 23(8):603-608.
[16] 刘铭, 张明军, 杨育才, 等. 保乳治疗乳腺癌患者临床病理特征与预后的相关性[J]. 安徽医学, 2019, 40(1):9-13.
文章导航

/